Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma
Meza L, Malhotra J, Favorito C, Pal S. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology 2021, 18: 21-33. PMID: 34766841, DOI: 10.2217/fon-2021-0570.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic renal cell carcinomaMetastatic urothelial carcinomaTargeted therapyTreatment of metastatic RCCMetastatic renal cellNonresponders to monotherapyRenal cell carcinomaIncrease clinical responsesImmunotherapy combinationsMetastatic RCCUrothelial carcinomaClinical responseCell carcinomaProgressive diseaseIO agentsTreatment optionsRenal cellsImmunotherapyQuality of lifeCabozantinibMonotherapyCarcinomaNovel approachesNonrespondersTherapy